

MIRA INFORM REPORT

Report No. :	535749
Report Date :	22.10.2018

IDENTIFICATION DETAILS

Name :	TAKEDA PHARMACEUTICAL COMPANY LTD
Registered Office :	4-1-1 Doshomachi Chuoku Osaka 540-8645
Country :	Japan
Financials (as on) :	31.03.2018
Date of Incorporation :	Jan., 1925
Com. Reg. No.:	1200-01-077461 (Osaka-Chuoku)
Legal Form :	Limited Company (Kabushiki Kaisha)
Line of Business :	Manufacturer of Pharmaceuticals
No. of Employees :	5,461

RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23rd January 2017)

MIRA's Rating :	A++
------------------------	-----

Credit Rating	Explanation	Rating Comments
A++	Minimum Risk	Business dealings permissible with minimum risk of default

Maximum Credit Limit :	Yen 19,721.0 Million
Status :	Excellent
Payment Behaviour :	Regular
Litigation :	Clear

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

NOTES:

Any query related to this report can be made on e-mail: while quoting report number, name and date.

ECGC Country Risk Classification List

Country Name	Previous Rating (30.06.2018)	Current Rating (30.09.2018)
Japan	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low Risk	A2
Moderately Low Risk	B1
Moderate Risk	B2
Moderately High Risk	C1
High Risk	C2
Very High Risk	D

JAPAN - ECONOMIC OVERVIEW

Over the past 70 years, government-industry cooperation, a strong work ethic, mastery of high technology, and a comparatively small defense allocation (slightly less than 1% of GDP) have helped Japan develop an advanced economy. Two notable characteristics of the post-World War II economy were the close interlocking structures of manufacturers, suppliers, and distributors, known as keiretsu, and the guarantee of lifetime employment for a substantial portion of the urban labor force. Both features have significantly eroded under the dual pressures of global competition and domestic demographic change.

Measured on a purchasing power parity basis that adjusts for price differences, Japan in 2017 stood as the fourth-largest economy in the world after first-place China, which surpassed Japan in 2001, and third-place India, which edged out Japan in 2012. For three postwar decades, overall real economic growth was impressive - averaging 10% in the 1960s, 5% in the 1970s, and 4% in the 1980s. Growth slowed markedly in the 1990s, averaging just 1.7%, largely because of the aftereffects of inefficient investment and the collapse of an asset price bubble in the late 1980s, which resulted in several years of economic stagnation as firms sought to reduce excess debt, capital, and labor. Modest economic growth continued after 2000, but the economy has fallen into recession four times since 2008.

Japan enjoyed an uptick in growth since 2013, supported by Prime Minister Shinzo ABE's "Three Arrows" economic revitalization agenda - dubbed "Abenomics" - of monetary easing, "flexible" fiscal policy, and structural reform. Led by the Bank of Japan's aggressive monetary easing, Japan is making modest progress in ending deflation, but demographic decline - a low birthrate and an aging, shrinking population - poses a major long-term challenge for the economy. The government currently faces the quandary of balancing its efforts to stimulate growth and institute economic reforms with the need to address its sizable public debt, which stands at 235% of GDP. To help raise government revenue, Japan adopted legislation in 2012 to gradually raise the consumption tax rate. However, the first such increase, in April 2014, led to a sharp contraction, so Prime Minister ABE has twice postponed the next increase, which is now scheduled for October 2019. Structural reforms to unlock productivity are seen as central to strengthening the economy in the long-run.

Scarce in critical natural resources, Japan has long been dependent on imported energy and raw materials. After the complete shutdown of Japan's nuclear reactors following the earthquake and tsunami disaster in 2011, Japan's industrial sector has become even more dependent than before on imported fossil fuels. However, ABE's government is seeking to restart nuclear power plants that meet strict new safety standards and is emphasizing nuclear energy's importance as a base-load electricity source. In August 2015, Japan successfully restarted one nuclear reactor at the Sendai Nuclear Power Plant in Kagoshima prefecture, and several other reactors around the country have since resumed operations; however, opposition from local governments has delayed several more restarts that remain pending. Reforms of the electricity and gas sectors, including full liberalization of Japan's energy market in April 2016 and gas market in April 2017, constitute an important part of Prime Minister Abe's economic program.

Under the Abe Administration, Japan's government sought to open the country's economy to greater foreign competition and create new export opportunities for Japanese businesses, including by joining 11 trading partners in the Trans-Pacific Partnership (TPP). Japan became the first country to ratify the TPP in December 2016, but the United States signaled its withdrawal from the agreement in January 2017. In November 2017 the remaining 11 countries agreed on the core elements of a modified agreement, which they renamed the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP). Japan also reached agreement with the European Union on an Economic Partnership Agreement in July 2017, and is likely seek to ratify both agreements in the Diet this year.

Source : CIA

COMPANY NAME AND ADDRESS

TAKEDA PHARMACEUTICAL COMPANY LTD

REGD NAME: Takeda Yakuhin Kogyo KK

MAIN OFFICE: 4-1-1 Doshomachi Chuoku Osaka 540-8645 JAPAN

Tel: 06-6204-2111 Fax: 06-6204-2880

*.. The is its Tokyo Office

URL: <http://www.takeda.com/>
E-Mail address: (thru the URL)

ACTIVITIES

Mfg of pharmaceuticals

BRANCHES

Tokyo, Sapporo, Sendai, Yokohama, Nagoya, Kobe, Kyoto, Takamatsu, Fukuoka, Hiroshima, Fukuoka, other (Tot 120)

OVERSEAS

USA (7), Canada, France, Italy, Germany, Austria, Switz, Spain, Portugal, Ireland, Netherlands, Sweden, Turkey, China, Taiwan, Thailand, Philippines, Indonesia, Singapore, Mexico (--subsidiaries), other (in approx 70 countries & territories)

R&D CENTERS

Osaka, Fujisawa, USA (3), UK (2), Singapore

FACTORIES

Osaka, Hikari; Italy, Ireland, China, Indonesia, USA, India, other (overseas factories total 17 countries)

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

OFFICERS

CHRISTOPHE WEBER, PRES Masato Iwasaki, dir
Andrew Plump, dir Masahiro Sakane, dir
Yoshiaki Fujimori, dir Emiko Azuma, dir

Yen Amount: In million Yen, unless otherwise stated

SUMMARY

FINANCES	FAIR	A/SALES	Yen 1,770,531 M
PAYMENTS	REGULAR	CAPITAL	Yen 77,923 M
TREND	STEADY	WORTH	Yen 1,997,424 M
STARTED	1925	EMPLOYES	5,461

COMMENT

PHARMACEUTICAL MFR.

FINANCIAL SITUATION COSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.

MAX CREDIT LIMIT: YEN 19,721.0 MILLION, 30 DAYS NORMAL TERMS

HIGHLIGHTS

This is a top-ranked time-honored pharmaceutical mfr, dating back to 1781 when Chobei Takeda set up a small firm, on his own, for selling Japanese & Chinese herbal medicine. In 1871, formed a cooperative union for purchasing and importing Western medicines. In 1985, started import of Western medicines. In 1895, began direct imports from England, US, Germany, Spain, other. In 1896, launched pharmaceutical mfg business. In 1907, obtained exclusive sales rights in Japan for products from German company Bayer. And in 1925 incorporated as Chobei Takeda & Co Ltd. The name changed as captioned in 1943. The subject steadily expanded its pharmaceutical business and even began exports to US, Russia and China. Has strength in drugs for lifestyle-related illness such as high blood pressure and diabetes. Leads others in genome research. In untapped markets, such as emerging countries, expanding own sales network, while planning marketing of generic products. The company purchased a US venture Millennium Pharmaceuticals in 2008, and has accelerated R&D of curatives for cancers. Also purchased Switzerland's Nycomed and obtained sales networks in Brazil, Russia and other emerging countries. CEO, Christophe Weber, was hired in from UK pharmaceutical firm took up the post in Apr 2014. It will step up efforts to penetrate emerging markets.

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

FINANCIAL INFORMATION

The sales volume for Mar/2018 fiscal term amounted to Yen 1,770,531 million, a 2.22% up from Yen 1,732,051 million in the previous term. The recurring profit was posted at Yen 217,205 million and the net profit at Yen 186,886 million, respectively, compared with Yen 143.346 million recurring loss and Yen 114,940 million net losses, respectively, a year ago.

For the current term ending Mar 2019 the recurring profit is projected at Yen 180,000 million and the net profit at Yen 140,000 million, on a 1.89% fall in turnover, to Yen 1,737,000 million.

The financial situation is considered FAIR and good for ORDINARY business engagements. Max credit limit is estimated at Yen 19,721.0 million, on 30 days normal terms.

REGISTRATION

Date Registered: Jan 1925
Regd No.: 1200-01-077461 (Osaka-Chuoku)
Legal Status: Limited Company (Kabushiki Kaisha)
Authorized: 3,500 million shares
Issued: 794,688,295 shares
Sum: Yen 77,923 million

Major shareholders (%): Master Trust Bank of Japan T (5.9), Nippon Life Ins (5.4), JP Morgan Chase Bank 385147 (4.4), State Street Bank West Treaty (1.8), others; foreign owners (35.2)

No. of shareholders: 247,487

Listed on the S/Exchange (s) of: Tokyo, Nagoya, Fukuoka, Sapporo

Nothing detrimental is known as to the commercial morality of executives.

Related companies: Takeda America Holdings Inc, Takeda Europe Holdings Inc, Nihon Pharmaceutical Co, other

OPERATION

Activities: Manufactures pharmaceuticals (Ethical Drugs) (96%), Health-care foods, others (4%).

Overseas Sales Ratio (67%)

Clients: [Pharmaceutical mfrs, wholesalers] Mediceo Corp, Alfresa Corp, Astem Co, Vital Net Inc, Nakakita Co, Nabelin Co, Miyazaki Osendo Shoten Corp, Tomita Pharmaceutical, Toshichi Co, other

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

TAKEDA PHARMACEUTICAL COMPANY LTD - 535749

PAGE NO. : 7

No. of accounts: 2,000
Domestic areas of activities: Nationwide

Suppliers: [Mfrs, wholesalers] Pfizer Japan Inc, Asuka Pharmaceutical Co, Senju Pharmaceutical Co, Biofermin Pharmaceutical Co, Nihon Pharmaceutical Co, other.

Payment record: Regular

Location: Business area in Osaka. Office premises at the caption address are owned and maintained satisfactorily.

Bank References:

SMBC (Osaka)
Mizuho Bank (Osaka)
Relations: Satisfactory

FINANCES

(In Million Yen)

Terms Ending:	31/03/2019	31/03/2018	31/03/2017	31/03/2016
Annual Sales	1,737,000	1,770,531	1,732,051	1,807,378
Recur. Profit	180,000	217,205	143,346	120,539
Net Profit	140,000	186,886	114,940	80,166
Total Assets		4,106,463	4,355,782	3,824,085
Current Assets		1,708,808	1,260,662	1,373,787
Current Liabs		737,509	1,366,091	857,213
Net Worth		1,997,424	1,894,261	1,948,692
Capital, Paid-Up		77,923	77,923	77,923
Div.P.Share(¥)		90.00	90.00	90.00
<Analytical Data>	(%)	(%)	(%)	(%)
S.Growth Rate	-1.89	2.22	-4.17	1.66
Current Ratio	..	231.70	92.28	160.26
N.Worth Ratio	..	48.64	43.49	50.96
R.Profit/Sales	10.36	12.27	8.28	6.67
N.Profit/Sales	8.06	10.56	6.64	4.44
Return On Equity	..	9.36	6.07	4.11

Notes: Forecast (or estimated) figures for the 31/03/2019 fiscal term.

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	INR 73.44
UK Pound	1	INR 95.65
Euro	1	INR 84.17
Yen	1	INR 0.65

Note: Above are approximate rates obtained from sources believed to be correct

INFORMATION DETAILS

Analysis Done by :	DIV
Report Prepared by :	NIT

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

RATING EXPLANATIONS

Credit Rating	Explanation	Rating Comments
A++	Minimum Risk	Business dealings permissible with minimum risk of default
A+	Low Risk	Business dealings permissible with low risk of default
A	Acceptable Risk	Business dealings permissible with moderate risk of default
B	Medium Risk	Business dealings permissible on a regular monitoring basis
C	Medium High Risk	Business dealings permissible preferably on secured basis
D	High Risk	Business dealing not recommended or on secured terms only
NB	New Business	No recommendation can be done due to business in infancy stage
NT	No Trace	No recommendation can be done as the business is not traceable

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

This score serves as a reference to assess SC's credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

- Financial condition covering various ratios
- Company background and operations size
- Promoters / Management background
- Payment record
- Litigation against the subject
- Industry scenario / competitor analysis
- Supplier / Customer / Banker review (wherever available)